Without a doubt, Inovio Pharmaceuticals (INO) is one of the year’s success stories. Heading into 2020, INO shares were going for $3.30 apiece. The stock is now priced at $13.30, an increase of a hefty 303%.As for how the biotech accumulated such impressive gains, the company has positioned itself as one to watch with its COVID-19 DNA vaccine candidate, INO-4800.However, even as investors’ optimism surges, some remain more skeptical. Among the skeptics is RBC Capital analyst Gregory Renza.The 5-star analyst rates INO shares a Sector Perform (i.e. Hold) along with a $10 price target. In other words, Renza expects shares …read more
Source:: Yahoo Finance
